Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | UBE2M | P61081 | 4/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6731406 | 0.86 | GRM2 (0.55) | CYP3A4TP53MAPTGRM2 | |
| SCHEMBL6730763 | 0.83 | CYP3A4 (0.59) | CYP3A4TP53MAPTGRM2 | |
| SCHEMBL6730973 | 0.83 | MAPT (0.51) | CYP3A4FAAHTP53MAPTGRM2 | |
| SCHEMBL6733035 | 0.82 | MAPT (0.54) | CYP3A4TP53MAPTGRM2 | |
| SCHEMBL6739041 | 0.81 | CYP3A4 (0.50) | CYP3A4TP53MAPTGRM2 | |
| SCHEMBL6735554 | 0.81 | NPC1 (0.48) | CYP3A4TP53MAPTGRM2 | |
| SCHEMBL6728076 | 0.81 | CYP3A4 (0.49) | CYP3A4UBE2MDCUN1D1TP53MAPT | |
| SCHEMBL7419432 | 0.81 | CYP3A4 (0.49) | CYP3A4TP53MAPTGRM2 | |
| SCHEMBL6730921 | 0.80 | NR1H4 (0.46) | CYP3A4TP53MAPT | |
| SCHEMBL6727717 | 0.80 | CYP19A1 (0.48) | CYP3A4TP53MAPTGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | claimed |
| EP-1255735-A2 | PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001056990-A2 | PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | CYP3A4 2786/4885FAAH 894/4885UBE2M 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.